Remyelination occurs in multiple sclerosis (MS) lesions but is generally considered to be insufficient. One of the major challenges in MS research is to understand the causes of remyelination failure and to identify therapeutic targets that promote remyelination. Activation of pancreatic endoplasmic reticulum kinase (PERK) signaling in response to endoplasmic reticulum stress modulates cell viability and function under stressful conditions. There is evidence that PERK is activated in remyelinating oligodendrocytes in demyelinated lesions in both MS and its animal model, experimental autoimmune encephalomyelitis (EAE). In this study, we sought to determine the role of PERK signaling in remyelinating oligodendrocytes in MS and EAE using transgenic mice that allow temporally controlled activation of PERK signaling specifically in oligodendrocytes. We demonstrated that persistent PERK activation was not deleterious to myelinating oligodendrocytes in young, developing mice or to remyelinating oligodendrocytes in cuprizone-induced demyelinated lesions. We found that enhancing PERK activation, specifically in (re)myelinating oligodendrocytes, protected the cells and myelin against the detrimental effects of interferon-g, a key proinflammatory cytokine in MS and EAE. More important, we showed that enhancing PERK activation in remyelinating oligodendrocytes at the recovery stage of EAE promoted cell survival and remyelination in EAE demyelinated lesions. Thus, our data provide direct evidence that PERK activation cell-autonomously enhances the survival and preserves function of remyelinating oligodendrocytes in immune-mediated demyelinating diseases. (Am J Pathol 2014, 184: 507e519; http://dx.
mouse model, we found that enhanced activation of PERK signaling specifically in mature oligodendrocytes protected the cells and myelin against inflammatory attack in EAE mice. 11 Mature oligodendrocytes in adult mice are only responsible for the slow replenishment of myelin components. In contrast, remyelinating oligodendrocytes must synthesize enormous amounts of membrane lipid and protein molecules to assemble myelin sheaths. The cells have extremely high metabolic rates. 4, 12 This feature makes remyelinating oligodendrocytes in MS and EAE demyelinated lesions more vulnerable to inflammatory attack and ER stress than mature oligodendrocytes. 12, 13 Our previous studies have shown that ER stress, induced by interferon-g (IFN-g), protects mature oligodendrocytes and myelin against inflammatory attack during the acute stage of EAE, but causes remyelinating oligodendrocyte apoptosis and remyelination failure at the recovery stage of EAE. 8, 14 Thus, in this study, we sought to dissect the precise role of PERK signaling in remyelinating oligodendrocytes in immunemediated demyelinating diseases exploiting PLP/Fv2E-PERK mice.
The immune cytokine, IFN-g, is thought to be a major contributing factor to poor remyelination in MS lesions. 1, 13 Our previous studies have shown that the presence of IFN-g in the CNS causes hypomyelination in young, developing mice, and remyelination failure in the cuprizone and EAE models. 14, 15 In this study, we demonstrate that persistent activation of PERK signaling does not affect the viability or function of (re)myelinating oligodendrocytes under normal conditions. Moreover, we show that enhancing PERK activation specifically in (re)myelinating oligodendrocytes attenuates IFN-geinduced hypomyelination in young, developing mice and IFN-geinduced remyelination failure in the cuprizone model. More important, we find that enhancing PERK activation specifically in remyelinating oligodendrocytes promotes remyelination in the EAE model. Our findings may lead to the development of therapeutic interventions to improve remyelination in patients with MS.
Materials and Methods

Mice, Cuprizone Treatment, and EAE Immunization
All mouse lines used were on the C57BL/6J background. PLP/Fv2E-PERK transgenic mice were maintained by mating with C57BL/6J mice. 11 GFAP/tTA;TRE/IFN-g; PLP/Fv2E-PERK triple transgenic mice were produced by crossing line 110 GFAP/tTA mice 14e16 with PLP/Fv2E-PERK mice, and then crossing the resulting progeny with line 184 TRE/IFN-g mice. 14e16 To repress the expression of the IFN-g transgene in the astrocytes of GFAP/tTA;TRE/ IFN-g;PLP/Fv2E-PERK mice, 0.05 mg/mL doxycycline was added to the drinking water and provided ad libitum from conception. 14e16 To activate the Fv2E-PERK transgene in the oligodendrocytes of PLP/Fv2E-PERK mice, the mice were given daily i.p. injections of AP20187 (Ariad Pharmaceuticals, Cambridge, MA); controls were injected with vehicle (4% ethanol, 10% PEG-400, and 2.0% Tween-20 in water) only. 11 To induce demyelination with cuprizone, 6-weekeold male mice were fed a diet of mouse chow containing 0.2% cuprizone (Sigma-Aldrich, St. Louis, MO) for up to 6 weeks. Subsequently, mice were returned to a normal diet for 3 weeks to allow remyelination to occur. 14 To induce EAE, 7-weekeold female mice were injected s.c. in the flank and at the tail base with 200 mg of myelin oligodendrocyte glycoprotein 35 to 55 peptideeemulsified incomplete Freund's adjuvant (BD Biosciences, San Jose, CA) supplemented with 600 mg of Mycobacterium tuberculosis (strainH37Ra; BD Biosciences). Two i.p. injections of 400 ng pertussis toxin (List Biological Laboratories, Denver, CO) were given 24 and 72 hours later. Clinical scores (0 indicates healthy; 1, flaccid tail; 2, ataxia and/or paresis of hind limbs; 3, paralysis of hind limbs and/or paresis of forelimbs; 4, tetra paralysis; and 5, moribund or death) were recorded daily. 8, 11 All animal procedures were conducted in complete compliance with the NIH Guide for the Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use Committee of the University of South Alabama (Mobile) and the University of Minnesota (Minneapolis).
Real-Time PCR
Deeply anesthetized mice were perfused with ice-cold PBS. RNA was isolated from the brain or the spinal cord using TRIzol reagent (Invitrogen, Carlsbad, CA) and treated with DNaseI (Invitrogen) to eliminate genomic DNA. Reverse transcription was performed using the iScript cDNA Synthesis Kit (Bio-Rad Laboratories, Hercules, CA). TaqMan real-time PCR was performed with iQSupermix (Bio-Rad Laboratories) on a Bio-Rad iQ Real-Time PCR detection system, as previously described. 8, 14, 17 Western Blot Analysis Tissues harvested from mice were rinsed in ice-cold PBS and were homogenized using a motorized homogenizer, as previously described. 15, 18 After incubating on ice for 15 minutes, the extracts were cleared by centrifugation at 18,000 Â g for 30 minutes, twice. The protein content of each extract was determined by DC Protein Assay (Bio-Rad Laboratories). Extracts (40 mg) were separated by SDS-PAGE and transferred to nitrocellulose. The blots were incubated with a primary antibody against myelin basic protein (MBP; 1:1000; Sternberger Monoclonals, Berkeley, CA), proteolipid protein (PLP; 1:1000; Santa Cruz Biotechnology, Santa Cruz, CA), or b-actin (1:5000; Sigma-Aldrich). This was followed by a horseradish peroxidaseeconjugated secondary antibody; after incubation with the ECL Detection 
IHC and TUNEL Staining
Anesthetized mice were perfused through the left cardiac ventricle with 4% paraformaldehyde in PBS. The tissues were removed, postfixed with paraformaldehyde, cryopreserved in 30% sucrose, embedded in optimal cutting temperature compound, and frozen on dry ice. Frozen sections were cut using a cryostat (10 mm thick). For immunohistochemistry (IHC), the sections were treated with À20 C acetone, blocked with PBS containing 10% goat serum and 0.1% Triton X-100, and incubated overnight with the primary antibody diluted in blocking solution. TUNEL staining was performed using the ApopTag kit (Chemicon, Temecula, CA), according to the manufacturer's instructions. The sections were mounted with Vectashield mounting medium with DAPI (Vector Laboratories) and visualized with a Nikon A1 confocal microscope or an Olympus FV1000 confocal microscope.
For cuprizone-treated mice, coronal sections of the fornix region of the corpus callosum, corresponding to Sidman sections 241 to 251, were selected for use, and all comparative analyses were restricted to the midline corpus callosum. 19 We quantified immunopositive cells by counting positive cells within the median of the corpus callosum, confined to an area of 0.15 mm 2 . We scored each slide immunostained for MBP on a scale of 0 to 4. A score of 0 indicated complete demyelination, and a score of 4 indicated normal myelination in the corpus callosum of adult mice. 14 For EAE mice, we counted immunopositive cells within the anterior funiculus directly medial to the anterior median fissure in the lumbar spinal cord and confined to an area of 0.1 mm 2 , as described in our previous articles. 8, 11 Toluidine Blue Staining and Electron Microscopy Analysis Mice were anesthetized and perfused with PBS containing 4% paraformaldehyde and 2.5% glutaraldehyde. For cuprizone-treated mice, brains were sliced into sections (1 mm thick). The section corresponding to the region of the fornix was trimmed, processed for electron microscopic (EM) analysis, and oriented so that a cross section of the corpus callosum was achieved. Ultrathin sections were cut, stained with uranyl acetate and lead citrate, and analyzed as described previously. 14 For EAE mice, the lumbar spinal cord was processed and embedded. Thin sections were cut, stained with toluidine blue, and analyzed as described previously. 11 Moreover, ultrathin sections were cut, stained with uranyl acetate and lead citrate, and analyzed as described previously. 11 We counted the total number of axons, calculated the total percentage of remyelinated axons, and measured the diameter of axons and the thickness of myelin sheaths using NIH ImageJ software version 1.45S (http://rsb. info.nih.gov/ij, last accessed November 1, 2012; NIH, Bethesda, MD), as described previously. 14, 17 Statistics Data are expressed as means AE SD. For quantitative histological analyses, the average number for each mouse was used for statistical analysis. If the data followed the gaussian distribution, multiple comparisons were statistically evaluated by the one-way analysis of variance test, followed by Tukey's test, and comparison of two groups was statistically evaluated by two-tailed t-test using SigmaStat 3.1 software (Hearne Scientific Software, Chicago, IL). If the data did not follow the gaussian distribution, a multiple comparison was statistically evaluated by the Kruskal-Wallis test, followed by a Dunns test, and comparison of two groups was statistically evaluated by the Mann-Whitney test using SigmaStat 3.1 software. Phenotypic differences among the groups were statistically evaluated by the c 2 test using SigmaStat 3.1 software. The relationship between myelin thickness and axon diameter was statistically evaluated by a linear regression using SigmaStat 3.1 software. P < 0.05 was considered significant.
Results
Persistent Activation of PERK Signaling Does Not Affect the Function of Myelinating Oligodendrocytes in Young, Developing Mice
In response to ER stress, PERK is activated through dimerization and autophosphorylation, enabling it to phosphorylate eIF2a. 20, 21 Phosphorylation of eIF2a inhibits global protein synthesis, but stimulates the expression of certain stress-induced genes, such as CCAAT enhancer binding protein homologous protein (CHOP) and growth arrest and DNA damage 34 (GADD34), by promoting the translation of the cytosolic transcription factor ATF4. We have generated PLP/Fv2E-PERK transgenic mice that allow temporally controlled activation of PERK signaling specifically in oligodendrocytes in the absence of ER stress. 11 These mice express Fv2E-PERK, an artificial PERK that is generated by fusing the eIF2a kinase effector domain of PERK to a polypeptide containing two modified FK506 binding domains (Fv2E), 22 under the control of the mouse PLP transcriptional control region. 23, 24 We have demonstrated that PLP/Fv2E-PERK mice express the transgene product Fv2E-PERK specifically in oligodendrocytes and that the activity of Fv2E-PERK is tightly controlled by administration of the dimerizer AP20187. 11 Robust myelination occurs in the mouse CNS between postnatal day (P) 7 and P21. 25 To determine whether PERK activation affects the myelinating function of oligodendrocytes, PLP/Fv2E-PERK mice were treated with 2 mg/kg AP20187 daily starting on P12 and ending on P21. AP20187-treated transgenic mice were indistinguishable from littermate transgenic mice treated with vehicle and from untreated wild-type mice. Real-time PCR analysis showed that AP20187 treatment significantly enhanced the expression of the PERK-responsive genes CHOP and GADD34 in the CNS of the transgenic mice ( Figure 1A ), but did not alter the expression of binding immunoglobulin protein, an ER stress-inducible gene not regulated by PERK signaling. 26 Meanwhile, Western blot analysis showed that AP20187 treatment did not change the levels of MBP and PLP in the CNS of 21-day-old PLP/Fv2E-PERK mice ( Figure 1B ). CC1 (a marker for oligodendrocytes) and p-eIF2a double immunostaining showed that AP20187 treatment markedly increased the level of p-eIF2a in most oligodendrocytes in the CNS of 21-day-old PLP/Fv2E-PERK mice ( Figures 1C and 2I ). Interestingly, we found that AP20187 treatment did not change the number of oligodendrocytes in the CNS of 21-day-old PLP/Fv2E-PERK mice ( Figures 1C and 2J ). Collectively, these data indicate that AP20187 treatment results in PERK activation in oligodendrocytes at non-physiological levels in transgenic mice with enforced expression of Fv2E-PERK specifically in oligodendrocytes, and that persistent activation of PERK signaling specifically in myelinating oligodendrocytes does not affect their viability or function.
Enhancing PERK Activation in Myelinating Oligodendrocytes Ameliorates IFN-geInduced Hypomyelination
IFN-g is thought to be a key proinflammatory cytokine in MS and EAE. 13, 27 We have generated transgenic mice that allow controllable delivery of IFN-g to the CNS using the tetracycline-controllable system. 16 Our previous studies have shown that the presence of IFN-g in the CNS during development causes oligodendrocyte loss and hypomyelination and that PERK signaling enhances the viability of myelinating oligodendrocytes in IFN-geexpressing mice. 15, 18 It has been well documented that the presence of IFN-g in the CNS reduces the viability of oligodendrocytes by activating T cells and microglia/macrophages. 28, 29 Moreover, recent studies have shown that PERK signaling influences the activity of T cells and macrophages. 30, 31 Thus, it is not clear whether the protective effects of PERK signaling on oligodendrocytes in IFN-geexpressing mice are the result of its actions in oligodendrocytes or in inflammatory cells.
To determine the cell-autonomous role of PERK signaling in myelinating oligodendrocytes in response to IFN-g, GFAP/tTA mice were crossed with PLP/Fv2E-PERK mice, Figure 1 Persistent activation of PERK signaling in myelinating oligodendrocytes does not affect developmental myelination. A: Real-time PCR analysis shows that AP20187 treatment significantly increases the expression of CHOP and GADD34 in the spinal cord of 21-day-old PLP/Fv2E-PERK mice, but does not affect the expression of binding immunoglobulin protein (BIP). N Z 3 animals. Error bars represent SD. B: Western blot analysis shows that AP20187 treatment does not affect the protein levels of MBP and PLP in the brain of 21-day-old PLP/Fv2E-PERK mice. N Z 3 animals. C: CC1 and p-eIF2a double immunostaining shows that p-eIF2a immunoreactivity is undetectable in oligodendrocytes in the brain of 21-day-old PLP/Fv2E-PERK mice treated with vehicle, but becomes detectable in oligodendrocytes (arrows) in AP20187-treated mice. Black bars, AP20187; gray bars, vehicle. N Z 3 animals. *P < 0.05. Scale bar Z 20 mm (C). ajp.amjpathol.org -The American Journal of Pathology and the resulting progeny were crossed with TRE/IFN-g mice to obtain GFAP/tTA;TRE/IFN-g;PLP/Fv2E-PERK triple transgenic mice. The triple transgenic mice were treated with doxycycline from conception to repress transgenic IFN-g expression. One group of the triple transgenic mice released from doxycycline at embryonic day 14 (E14) was treated with 0.5 mg/kg AP20187 daily starting on P12 (IFNgþ; AP20187 mice). A second group of the triple transgenic mice released from doxycycline at E14 was treated with vehicle (IFN-gþ; vehicle mice). The triple transgenic mice never released from doxycycline were treated with either AP20187 or vehicle to serve as controls (IFN-gÀ; AP20187 mice and IFN-gÀ; vehicle mice, respectively). IFN-gþ; vehicle mice exhibited tremor and ataxia, as described in our previous articles. 15, 17, 18 Interestingly, IFN-gþ; AP20187 mice displayed a significantly milder tremoring phenotype than IFN-gþ; vehicle mice ( Table 1) .
As expected, CC1 and p-eIF2a double immunostaining showed that AP20187 treatment increased the level of p-eIF2a in oligodendrocytes in control mice and IFN-ge expressing mice ( Figure 2I ). We also found that, although AP20187 treatment did not affect oligodendrocyte numbers in the CNS of 21-day-old control animals ( Figure 2 , A, B, and J), it did attenuate oligodendrocyte loss in the CNS of 21-day-old IFN-geexpressing mice (Figure 2 , C, D, and J). Moreover, MBP immunostaining and Western blot analyses showed that AP20187 treatment did not affect the myelination process in the CNS of control animals, but significantly alleviated myelin loss in the CNS of 21-day-old IFN-geexpressing mice (Figure 2 , EeH, K, and L). In Figure 2 Enhancing PERK activation in myelinating oligodendrocytes protects the cells and myelin against IFN-g in young, developing mice. AeD and J: CC1 immunostaining shows that AP20187 treatment does not alter the number of oligodendrocytes in the corpus callosum of 21-day-old control mice, but significantly attenuates IFN-geinduced oligodendrocyte loss in IFN-geexpressing mice. N Z 3 animals. EeH: MBP immunostaining shows that AP20187 treatment does not affect the degree of myelination in the corpus callosum of 21-day-old control mice, but ameliorates IFN-geinduced myelin loss in IFN-geexpressing mice. N Z 3 animals. I: CC1 and p-eIF2a double immunostaining shows that the presence of IFN-g in the CNS moderately increases the percentage of CC1-positive cells that are double positive for CC1 and p-eIF2a in the corpus callosum of 21-day-old vehicle-treated mice (IFN-gþ; vehicle mice versus IFN-gÀ; vehicle mice), and that >80% of oligodendrocytes are p-eIF2a positive in the corpus callosum of 21-day-old AP20187-treated mice (IFN-gÀ; AP20187 mice and IFN-gþ; AP20187 mice). N Z 3 animals. K and L: Western blot analysis shows that AP20187 treatment does not alter the level of MBP in the brain of 21-day-old control mice, but significantly attenuates the reduction of MBP level in mice expressing IFN-g. The MBP protein level is reported relative to b-actin. N Z 3 animals. I, J, and L: Error bars represent SD. *P < 0.05. Scale bars: 20 mm (AeD); 50 mm (EeH). addition, PDGFaR immunostaining showed that AP20187 treatment did not significantly alter the number of oligodendrocyte progenitor cells (OPCs) in the CNS of 21-dayold control mice or IFN-geexpressing mice (data not shown). Collectively, these data suggest that enhancing PERK activation in myelinating oligodendrocytes protects the cell and myelin against the cytotoxicity of IFN-g, resulting in the attenuation of the tremoring phenotype in the mice.
Our previous study demonstrated that inflammatory cells (T cells and microglia/macrophages) do not express the transgene product Fv2E-PERK in PLP/Fv2E-PERK mice. 11 Moreover, recent studies have shown that AP20187 has no noticeable effect on the functions of inflammatory cells. 11, 32 Therefore, we further sought to exclude the possibility that AP20187 treatment influences the IFN-geinduced inflammatory response in GFAP/tTA;TRE/IFN-g;PLP/Fv2E-PERK mice. As expected, we found that AP20187 treatment did not significantly affect the expression of IFN-g in the CNS of control mice or IFN-geexpressing mice ( Figure 3I ). Consistent with our previous studies, 17, 18 we found that the presence of IFN-g in the CNS moderately recruited T cells into the CNS, markedly activated microglia/macrophages, and dramatically increased the expression of TNF-a ( Figure 3 ). Nevertheless, AP20187 treatment did not significantly alter T-cell recruitment, microglia/macrophage activation, or TNF-a expression in the CNS of 21-day-old control mice or IFN-geexpressing mice. Therefore, it is unlikely that AP20187 treatment attenuates the IFN-ge induced oligodendrocyte loss and hypomyelination in GFAP/tTA;TRE/IFN-g;PLP/Fv2E-PERK mice by altering the inflammatory response. Taken together, these results demonstrate that PERK activation cell-autonomously preserves the survival and function of myelinating oligodendrocytes in response to IFN-g.
Persistent Activation of PERK Signaling Does Not Affect the Function of Remyelinating Oligodendrocytes Derived from OPCs in Adult Mice
Although the cellular mechanisms responsible for remyelination and developmental myelination share many similarities, multiple lines of evidence suggest they also differ in several important ways. 33 Therefore, we investigated whether activation of PERK signaling is detrimental to remyelinating oligodendrocytes derived from OPCs in adult mice using the cuprizone model. When young adult C57BL/ 6J male mice are fed 0.2% cuprizone in their diet, mature oligodendrocytes in the corpus callosum are lost, which is followed by complete demyelination by 5 weeks of cuprizone exposure. OPCs accumulate within the demyelinated lesion, and mature oligodendrocytes repopulate the area beginning at approximately 6 weeks into the treatment protocol, resulting in complete remyelination after several weeks of cuprizone removal. 34 It is generally believed that the cuprizone model is one of the best mouse models to understand the processes of demyelination and remyelination in the CNS. Recently, the cuprizone model is increasingly used to study the mechanisms of remyelination in demyelinating diseases of the CNS, such as MS. 35, 36 Six-week-old male PLP/Fv2E-PERK mice on the C57BL/ 6J background were treated with 0.2% cuprizone chow for up to 6 weeks. To determine whether PERK activation in mature oligodendrocytes affects cuprizone-induced demyelination, PLP/Fv2E-PERK mice were treated with 0.5 mg/kg AP20187 or vehicle daily starting 2 days before cuprizone exposure. In accordance with previous studies, 34 there was almost complete oligodendrocyte loss and demyelination in the corpus callosum of vehicle-treated mice after 5 weeks of cuprizone treatment (data not shown). We found that AP20187 treatment did not alter oligodendrocyte loss or demyelination in the corpus callosum of PLP/Fv2E-PERK mice after 5 weeks of cuprizone treatment (data not shown). Therefore, these data suggest that PERK activation specifically in mature oligodendrocytes has no effect on cuprizone-induced oligodendrocyte loss and demyelination.
To determine the effects of PERK activation on remyelinating oligodendrocytes, PLP/Fv2E-PERK mice, which had been treated with 0.2% cuprizone chow for 6 weeks, were subsequently returned to a normal diet for 3 weeks to allow remyelination to occur. The Fv2E-PERK was activated in remyelinating oligodendrocytes by the daily administration of 0.5 mg/kg AP20187 starting on the day of cuprizone removal. Controls were injected with vehicle only. As expected, CC1 and p-eIF2a double immunostaining showed that AP20187 treatment markedly increased the level of p-eIF2a specifically in oligodendrocytes in the corpus callosum (Supplemental Figure S1A ). Moreover, we found that AP20187 treatment did not significantly affect the number of remyelinating oligodendrocytes or the degree of remyelination in the demyelinated lesions after 3 weeks of cuprizone removal (Supplemental Figure S1 and Figures 4 and 5) . Thus, these data indicate that the persistent activation of PERK signaling in remyelinating oligodendrocytes, derived from OPCs in adult mice, does not affect their viability or function.
Enhancing PERK Activation in Remyelinating Oligodendrocytes Ameliorates IFN-geInduced Remyelination Failure in Cuprizone-Induced Demyelinated Lesions
We have shown that the presence of IFN-g in the CNS induces remyelinating oligodendrocyte apoptosis and suppresses remyelination in the demyelinated lesions in the cuprizone model, and that PERK haploinsufficiency exacerbates IFN-geinduced remyelination failure. 14 We used the cuprizone model to determine whether enhancing PERK activation in remyelinating oligodendrocytes would have the opposite effect of promoting cell survival and remyelination in response to IFN-g. Six-week-old male GFAP/tTA;TRE/IFN-g;PLP/Fv2E-PERK triple transgenic mice that had been maintained on doxycycline from conception were simultaneously treated with 0.2% cuprizone chow and released from doxycycline. The triple transgenic mice were treated with cuprizone chow for 6 weeks, and then returned to a normal diet for 3 weeks. One group of these triple transgenic mice was treated with 0.5 mg/kg AP20187 daily starting on the day of cuprizone removal (IFN-gþ; AP20187 mice). A second group of these triple-transgenic mice was treated with vehicle (IFN-gþ; vehicle mice). Triple transgenic mice that were never released from doxycycline, but were treated with 0.2% cuprizone chow, followed by daily injections of AP20187 or vehicle starting on the day of cuprizone removal, were used as controls (IFN-gÀ; AP20187 mice and IFN-gÀ; vehicle mice, respectively). As expected, we found that AP20187 treatment elevated the level of p-eIF2a in remyelinating oligodendrocytes in the corpus callosum of control animals and IFN-geexpressing mice (data not shown), and that AP20187 treatment did not significantly alter the number of remyelinating oligodendrocytes or the degree of remyelination in the corpus callosum of control animals (Figures 4 and 5) .
Consistent with our previous study, 14 we found that the presence of IFN-g in the CNS significantly reduced the number of remyelinating oligodendrocytes and the extent of remyelination in the corpus callosum of IFN-gþ; vehicle mice after 3 weeks of cuprizone removal compared with control IFN-gÀ; AP20187 mice and IFN-gÀ; vehicle mice (Figures 4 and 5) . Interestingly, the number of remyelinating oligodendrocytes in the corpus callosum of IFN-gþ; AP20187 mice was significantly increased compared with IFN-gþ; vehicle mice (Figure 4, CeE) . Furthermore, CC1 and TUNEL double labeling showed that AP20187 treatment significantly reduced the number of apoptotic remyelinating oligodendrocytes in the corpus callosum of IFN-gþ; AP20187 mice after 3 weeks of cuprizone removal compared with IFN-gþ; vehicle mice (Figure 4 , C, D, and F). MBP immunostaining showed that AP20187 treatment attenuated the degree of remyelination failure in the demyelinated lesions of IFN-geexpressing mice after 3 weeks of cuprizone removal ( Figure 5 , C, D, and I). More important, EM analysis confirmed that AP20187 treatment significantly increased the percentage of remyelinated axons in the corpus callosum of IFN-gþ; AP20187 mice after 3 weeks of cuprizone removal compared with IFN-gþ; vehicle mice ( Figure 5, G, H, and J) . Nevertheless, PDGFaR immunostaining showed that AP20187 treatment did not significantly alter the number of OPCs in the corpus callosum of either control mice or IFN-geexpressing mice (data not shown). As expected, we also found that AP20187 treatment did not affect T-cell infiltration or microglia/ macrophage activation in the corpus callosum of control animals or IFN-geexpressing mice (data not shown). Collectively, these data demonstrate that PERK activation in remyelinating oligodendrocytes promotes cell survival and remyelination in response to IFN-g. 
Enhancing PERK Activation in Remyelinating Oligodendrocytes Promotes Remyelination in EAE Demyelinated Lesions
Although several studies have shown that ER stress is activated in multiple cell types in MS and EAE demyelinated lesions, including oligodendrocytes, T cells, and microglia/macrophages, 8e10,37 the role that ER stress plays in these cell types during the remyelination process remains unknown. It is believed that inflammatory mediators, such as immune cytokines and reactive oxygen/nitrogen species, contribute significantly to oligodendrocyte death in MS and EAE. 12, 38 Several lines of evidence have suggested that PERK activation protects cells against these inflammatory mediators and ER stress. 11, 22 Thus, we further determine the cell-autonomous role of PERK activation in remyelinating oligodendrocytes in the EAE model. Seven-week-old female PLP/Fv2E-PERK mice were immunized with myelin oligodendrocyte glycoprotein 35 to 55 peptide to induce EAE. These mice developed neurological signs of disease starting at approximately postimmunization day (PID) 14, and started recovering from EAE at approximately PID22 11 ( Figure 6 ). Remyelination in MS and EAE demyelinated lesions has been reported to initiate during the acute stage of diseases. 39, 40 To activate PERK signaling in the remyelinating oligodendrocytes within the demyelinated lesions at the recovery stage of EAE, PLP/Fv2E-PERK mice were given i.p. injections of 0.5 mg/kg AP20187 daily starting on PID20; controls were injected with vehicle. CC1 and p-eIF2a double immunostaining showed that a few oligodendrocytes were p-eIF2a positive in the lumbar spinal cord of PLP/Fv2E-PERK mice treated with vehicle. As expected, the level of p-eIF2a was markedly increased in oligodendrocytes in PLP/Fv2E-PERK mice treated with AP20187 (Supplemental Figure S2) . Nevertheless, AP20187 treatment did not significantly change the clinical symptoms of mice with EAE ( Figure 6 ).
Next, we determined whether AP20187 treatment influences the viability and function of remyelinating oligodendrocytes in the demyelinated lesions of PLP/Fv2E-PERK mice. Our previous studies have shown that oligodendrocytes were largely lost in EAE demyelinated lesions at the peak of disease. 8, 11 Immunostaining for ASPA, a marker for oligodendrocytes, 41, 42 showed that at PID34, a few oligodendrocytes were present in the demyelinated lesions in the lumbar spinal cord of PLP/Fv2E-PERK mice treated with vehicle. AP20187 treatment significantly increased the number of oligodendrocytes in the demyelinated lesions of PLP/Fv2E-PERK mice at PID34 (Figure 7, AeC) ; however, there were significantly fewer oligodendrocytes in the demyelinated lesions of AP20187-treated mice than in the matched regions in adult naïve PLP/Fv2E-PERK mice ( Figure 7C and Supplemental Figure S3 , AeC). Furthermore, EM analysis was used to observe remyelinated axons, which are recognizable by myelin sheaths that are thin in relation to axon diameter, 12 in the demyelinated lesions at PID34. Importantly, there were significantly more remyelinated axons in the demyelinated lesions of AP20187-treated mice than of vehicle-treated mice (Figure 7 , D and F). AP20187 treatment also significantly increased the myelin thickness of remyelinated axons in PLP/Fv2E-PERK mice at Figure 7G ). Nevertheless, AP20187 treatment did not significantly change the total number of axons in the demyelinated lesions of PLP/Fv2E-PERK mice ( Figure 7E and Supplemental Figure S3 , DeF). As expected, there were significantly fewer total axons in the demyelinated lesions of PLP/Fv2E-PERK mice treated with either AP20187 or vehicle than in the matched regions in adult naïve PLP/Fv2E-PERK mice ( Figure 7E and Supplemental Figure S3 , DeF). Meanwhile, PDGFaR immunostaining showed that AP20187 treatment did not significantly alter the number of OPCs in the demyelinated lesions of PLP/Fv2E-PERK mice (data not shown). Taken together, these data demonstrate that PERK activation in remyelinating oligodendrocytes promotes cell survival and remyelination in EAE demyelinated lesions.
PID34 (
There is no evidence that AP20187 treatment alone has any noticeable effect on mice under physiological or pathological conditions. 32,43e45 More important, our previous study demonstrated that AP20187 treatment does not affect the inflammatory response in PLP/Fv2E-PERK mice undergoing EAE. 11 Consistently, we found that AP20187 treatment did not significantly alter the number of CD3positive T cells or the number of CD11b-positive microglia/ macrophages in the demyelinated lesions of PLP/Fv2E-PERK mice at PID34 (Figure 8 ). Thus, it is unlikely that AP20187 treatment promotes remyelination in the EAE demyelinated lesions of PLP/Fv2E-PERK mice by altering the inflammatory response.
Discussion
MS is a chronic inflammatory demyelinating disease of the CNS. 46 Remyelination is necessary to restore neurological function in patients with MS; however, the remyelination is considered to be insufficient. 1, 2 It is generally believed that the accumulated load of demyelinated lesions that fail to remyelinate leads to the progressive deterioration of neurological function in patients with MS. One of the major challenges in MS research is to understand the causes of remyelination failure and to develop therapeutic strategies that promote oligodendrocyte regeneration and remyelination. Several lines of evidence have suggested that ER stress in oligodendrocytes influences the development of myelin disorders. 4, 47 PERK signaling activated in response to ER stress is essential to preserve cell function and survival under stressful conditions. Nevertheless, PERK signaling is not exclusively beneficial to cell survival. Persistent activation of PERK signaling can result in cell apoptosis through the induction of CHOP, a pro-apoptotic transcription factor, in ER-stressed cells. 6, 7 Interestingly, a previous study showed that CHOP induction promotes the survival of ER-stressed myelinating oligodendrocytes in the mouse models of Pelizaeus-Merzbacher disease. 48 The unique function of CHOP in myelinating oligodendrocytes raises the possibility that PERK signaling has particularly beneficial effects on (re)myelinating oligodendrocytes.
Activation of PERK signaling has been observed in oligodendrocytes in MS and EAE demyelinated lesions. 9, 10, 37 Nevertheless, the role that it plays in remyelinating oligodendrocytes in these diseases remains ambiguous. We have generated transgenic mice that allow temporally controlled activation of PERK signaling specifically in oligodendrocytes. 11 In this study, by using the unique mouse model, we provide direct evidence that PERK activation in remyelinating oligodendrocytes is cytoprotective, promoting remyelination in demyelinated lesions in immune-mediated demyelinating diseases. First, we demonstrated that persistent activation of PERK signaling was not deleterious to myelinating oligodendrocytes in young, developing mice or to remyelinating oligodendrocytes in cuprizone-induced demyelinated lesions. Second, we showed that specifically enhancing PERK activation in myelinating oligodendrocytes protects the cells and myelin against the detrimental effects of the immune cytokine, IFN-g, during development. Third, we showed that enhanced PERK activation in remyelinating oligodendrocytes attenuated IFN-geinduced cell apoptosis and remyelination failure in the cuprizone model. Fourth, we showed that enhanced PERK activation in remyelinating oligodendrocytes at the recovery stage of EAE facilitated oligodendrocyte regeneration and remyelination in EAE demyelinated lesions. Our previous work demonstrated that PDGFaR-positive OPCs and inflammatory cells (T cells and microglia/macrophages) do not express the transgene product, Fv2E-PERK, in PLP/Fv2E-PERK mice 11 and that AP20187 treatment does not affect the proliferation of OPCs or the activity of inflammatory cells in mice undergoing EAE. 11 Consistent with these results, we found that PERK activation in (re)myelinating oligodendrocytes had no noticeable effect on OPCs or inflammatory cells. Although the precise molecular mechanisms by which PERK signaling protects remyelinating oligodendrocytes against inflammatory mediators and ER stress in immune-mediated demyelinating diseases remain to be elucidated, the results presented herein suggest that the manipulation of PERK signaling in remyelinating oligodendrocytes could promote myelin repair in MS demyelinated lesions.
IFN-g is thought to be a major contributing factor to poor remyelination in MS lesions. 1, 13 Our previous studies have shown that the deleterious effects of IFN-g on developmental myelination and remyelination are mediated, at least in part, by PERK signaling. 14, 15, 18 The data concerning the effects of PERK signaling, however, appear contradictory. We showed that PERK haploinsufficiency exacerbated IFNgeinduced myelinating oligodendrocyte loss and hypomyelination in young, developing mice and IFN-geinduced remyelinating oligodendrocyte apoptosis and remyelination failure in the cuprizone model. 14, 15 In contrast, although our previous publication showed that global inactivation of the GADD34 gene, which encodes the stress-inducible regulatory subunit of a phosphatase complex that dephosphorylates eIF2a, increased the activity of the PERK-eIF2a pathway and ameliorated IFN-geinduced myelinating oligodendrocyte loss and hypomyelination in young, developing mice, 18 we found that GADD34 inactivation exacerbated IFN-geinduced remyelinating oligodendrocyte death and remyelination failure in cuprizone-induced demyelinated lesions (unpublished data, W. Lin). It is known that IFN-g influences the viability of oligodendrocytes in the CNS by regulating the functions of T cells and microglia/macrophages. 28, 29 Moreover, recent studies have shown that PERK signaling is a potent regulator of the functions of T cells and macrophages in inflammatory diseases. 30, 31, 49 Clearly, the mouse models used in our previous studies did not allow us to determine the specific contribution of oligodendrocytes or inflammatory cells (T cells and microglia/macrophages) to the contradictory effects of PERK signaling on developmental myelination and remyelination in response to IFN-g. By using a transgenic mouse model that allows for the temporally controlled activation of PERK signaling specifically in oligodendrocytes, we showed herein that PERK activation in both myelinating oligodendrocytes and remyelinating oligodendrocytes is beneficial in response to IFN-g. Therefore, we demonstrated that PERK activation in (re)myelinating oligodendrocytes protects these cells cell-autonomously against the cytotoxicity of IFN-g, resulting in enhanced (re) myelination. In addition, these results suggest that the antagonistic effects of PERK signaling on developmental myelination and remyelination in response to IFN-g are likely the result of PERK's effects on inflammatory cells (T cells or microglia/macrophages).
The principle function of oligodendrocytes is to produce myelin, the unique multilamellar sheath that wraps around axons, in the CNS. 25 Because of the enormous surface area of myelin, each (re)myelinating oligodendrocyte must synthesize a large quantity of myelin proteins during the active phase of myelination. 50 Recent studies have suggested that oligodendrocytes are highly sensitive to the disruption of protein translation. 4, 51 There is evidence that loss-offunction mutations of translation initiation factor, eIF2B, exclusively affect the CNS white matter in most cases of vanishing white matter disease, a fatal autosomal-recessive hypomyelinating disease. 52, 53 Although PERK activation protects cells against cytotoxic effects of inflammatory mediators and ER stress by phosphorylating eIF2a, 11, 22 p-eIF2a inhibits global protein biosynthesis by suppressing the activity of eIF2B, with the two proteins forming a non-productive p-eIF2aeeIF2B complex. 54 Therefore, it was necessary to exclude the possibility that PERK activation promotes (re)myelinating oligodendrocyte survival but impairs their myelinating function. Importantly, we showed herein that PERK activation in (re)myelinating oligodendrocytes did not suppress the (re)myelination process under normal or pathological conditions. A previous study had shown that AP20187 can penetrate the blood-brain barrier; however, its blood-brain barrier permeability is moderate. 55 Thus, our data likely suggest that the treatment with a low dosage of AP20187 (0.5 or 2 mg/kg) moderately activates PERK signaling in oligodendrocytes in PLP/Fv2E-PERK mice and that moderate activation of PERK signaling has no significant effect on the function of remyelinating oligodendrocytes in immune-mediated demyelinating diseases. On the other hand, it could be interesting to determine whether strong activation of PERK signaling in myelinating oligodendrocytes would lead to oligodendrocyte dysfunction, reproducing vanishing white matter disease in mice.
Although we showed herein that enhanced PERK activation in remyelinating oligodendrocytes promoted remyelination in EAE demyelinated lesions, we found that starting AP20187 treatment on PID20 did not significantly affect the severity of the clinical symptoms in PLP/Fv2E-PERK mice during the recovery stage of disease. It is believed that inflammation contributes significantly to the clinical symptoms of EAE. 56 Recent studies also suggest that axon degeneration contributes to the clinical symptoms of MS and EAE and is the principal cause of chronic disability in MS. 57, 58 Axon degeneration largely occurs during the acute
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The American Journal of Pathologyajp.amjpathol.org stage of EAE. It is not surprising that enhanced PERK activation in oligodendrocytes at the recovery stage of disease did not alter the degree of axon loss in EAE demyelinated lesions ( Figure 7E and Supplemental Figure S3 , DeF). Moreover, we showed that starting AP20187 treatment on PID20 did not alter the degree of inflammation in PLP/Fv2E-PERK mice at the recovery stage of EAE. Therefore, it is possible that the lack of effect of oligodendrocyte-specific enhancement of PERK activation on inflammation and axon loss in EAE mice is responsible for the minimal change in the clinical symptoms at the recovery stage of the disease. Clearly, the inability of enhanced PERK activation in oligodendrocytes to ameliorate EAE clinical symptoms, despite its beneficial effects on remyelination, is deserving of additional study.
In summary, the results presented herein demonstrate that activation of PERK signaling in remyelinating oligodendrocytes cell-autonomously promotes cell survival, and subsequently results in enhanced remyelination in immunemediated demyelinating diseases. Currently, there is no effective therapy for MS that promotes oligodendrocyte regeneration and myelin repair. This study suggests that therapeutic strategies that activate PERK signaling in remyelinating oligodendrocytes may have beneficial effects on the restoration of neurological function and may delay disability progression in patients with MS.
